Gene Therapy

Edited by: Stephen P. Hoffert M.R. Knowles, K.W. Hohneker, Z. Zhou, J.C. Olson, T.L. Noah, P. Hu, M.W. Leigh, J.F. Engelhardt, L.J. Edwards, K.R. Jones, M. Grossman, J.M. Wilson, L.G. Johnson, R.C. Boucher, "A controlled study of adenoviral-vector-mediated gene transfer in the nasal epithelium of patients with cystic fibrosis," New England Journal of Medicine, 333:823-31, 1995. (Cited in more than 100 papers through September 1997) Comments by Richard C. Boucher, University of North Carolina Cy

Written byStephen Hoffert
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

Edited by: Stephen P. Hoffert
M.R. Knowles, K.W. Hohneker, Z. Zhou, J.C. Olson, T.L. Noah, P. Hu, M.W. Leigh, J.F. Engelhardt, L.J. Edwards, K.R. Jones, M. Grossman, J.M. Wilson, L.G. Johnson, R.C. Boucher, "A controlled study of adenoviral-vector-mediated gene transfer in the nasal epithelium of patients with cystic fibrosis," New England Journal of Medicine, 333:823-31, 1995. (Cited in more than 100 papers through September 1997)

Comments by Richard C. Boucher, University of North Carolina Cystic Fibrosis-Pulmonary Research and Treatment Center.

The cystic fibrosis transmembrane regulator (CFTR) gene was isolated as the cause of cystic fibrosis (CF) in 1989. By 1993, gene therapy treatments for patients with CF began in earnest. While early studies reported some success with gene transfer, experimental flaws cast doubt on those results. In 1995, Richard C. Boucher, a professor of medicine at the University of North Carolina, Chapel Hill (UNC-CH), would publish a model clinical study ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies